Roche announced that it has launched the CoaguChek Pro II system in countries accepting the CE Mark.1 CoaguChek Pro II combines two tests in a single device – the activated partial thromboplastin time (aPTT) test and the prothrombin time (PT) test with extended claims – for greater insight into patients’ coagulation status in acute care settings, such as emergency rooms, operating rooms and intensive care units, or anticoagulation clinics.
CoaguChek Pro II can be used to identify the presence of vitamin K antagonists in patients with acute bleeding or to detect possible coagulation factor deficiency. It can also be used to monitor the real time anticoagulant effect in patients treated with unfractionated heparin.
CoaguChek Pro II provides results without having to spend valuable time waiting for lab results. Instead, ER staff can run the test on the handheld device next to the patient.2
Transferring critical information when and where it is needed is possible with built-in Wi-Fi connectivity. Test results can be automatically transmitted in real time from the device to patients’ electronic health records, ensuring that vital information is immediately available at every point of care. Furthermore, it eliminates transcription steps, thereby streamlining workflow and reducing the possibility of human error.
CoaguChek Pro II also has a first-in-market QR code feature. Test results can be transformed into a QR code and transferred, for example via mobile phone. This can be valuable in remote settings, allowing a visiting nurse to measure coagulation values for a homebound patient, and send the result using cellular data to a doctor. Based on the result, the physician can provide a new anticoagulant dosing schedule in real time – all while the nurse remains with the patient.
“Building on the best in class quality, CoaguChek Pro II is small, light and convenient with accuracy and precision that our customers have come to expect from CoaguChek® over the past 20 years,” said Jean-Claude Gottraux, Head of Roche Professional Diagnostics. “As the latest addition to the CoaguChek family, CoaguChek Pro II expands our coagulation point of care offering beyond self-monitoring and doctors’ offices to also include more specialised settings such as the ER and OR.”
References
- Local product availability may vary independently from CE Mark approval.
- Theusinger OM, Stein P, Levy JH. Point of care and factor concentrate-based coagulation algorithms. Transfus Med Hemother 2015;42:115–21.
